ashfaq Ahmad

Dr. ashfaq Ahmad

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
TPTirath Patel
Tirath Patel
FHFathimathul Henna
Fathimathul Henna
AAashfaq Ahmad
ashfaq Ahmad
AAAyesha Ahmad
Ayesha Ahmad
NHNoor Ul Huda
Noor Ul Huda
NANikhilesh Anand
Nikhilesh Anand
Background: Epilepsy is a chronic neurological disorder characterized by recurrent seizures, affecting approximately 50 million individuals globally. While conventional antiseizure medications (ASMs) control seizures in 70–80% of patients, about 30% experience drug resistance or intolerable side effects, necessitating alternative approaches. Objective: To critically compare the efficacy, safety, and accessibility of conventional and emerging therapies for epilepsy, particularly in the context of treatment-resistant cases and global disparities in care. Methods: This narrative review synthesized evidence from 120 peer-reviewed articles published between 2015 and 2025. Literature was retrieved from PubMed, Embase, Cochrane Library, and Scopus using predefined search terms related to epilepsy treatments. Comparative analysis included therapeutic mechanisms, clinical outcomes, and implementation barriers. Results: Conventional treatments such as phenytoin, valproate, levetiracetam, surgical resection, ketogenic diet, and vagus nerve stimulation (VNS) offer 70–80% seizure control. However, emerging therapies are gaining prominence. Cannabidiol (CBD) demonstrates a 30–50% seizure reduction, while responsive neurostimulation (RNS) achieves 50–70% efficacy, especially in drug-resistant epilepsy. Despite these advancements, a 75% treatment gap persists in low-income countries due to limited resources, access, and trained personnel. Conclusion: Emerging therapies hold promise for managing refractory epilepsy, yet global disparities limit their reach. Precision medicine strategies must be coupled with efforts to improve access in underserved regions. This review provides practical insights for personalized care and advocates for increased investment in equitable treatment infrastructure.

14 August 2026 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
MAMuhammad Faizan Ali
Muhammad Faizan Ali
HAHusnain Ahmad
Husnain Ahmad
MQMaria Qadri
Maria Qadri
Sherif EltawansySherif Eltawansy
Sherif Eltawansy
MAMuhammad Usman Arshad
Muhammad Usman Arshad
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida

21 January 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
TPTirath Patel
Tirath Patel
AAashfaq Ahmad
ashfaq Ahmad
KIKinza Irshad
Kinza Irshad
RURahat Ullah
Rahat Ullah
ANAnaya Noor
Anaya Noor
NANikhilesh Anand
Nikhilesh Anand
Background: Lucid dreaming (LD), which involves being aware of and controlling one’s dreams, is of particular interest in the study of consciousness and has potential therapeutic applications. In this narrative review, we highlight the neurobiological aspects of LD, specifically its mechanisms associated with the activation of prefrontal and parietal areas, increased gamma oscillations, and the influence of cholinergic and dopaminergic signaling, primarily during rapid eye movement (REM) sleep. Objective: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams. Methods: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson’s] and healthy individuals (18–45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated. Results: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns. Conclusion: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.

15 July 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
ABAsia Batool
Asia Batool
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
RFRamzan Farooq
Ramzan Farooq
MAMakhzan Ali Akbar
Makhzan Ali Akbar
AAAlisha Ahmed
Alisha Ahmed
HAHasibullah Aminpoor
Hasibullah Aminpoor
Background: Cutaneous aging is characterized by progressive degradation of the extracellular matrix, manifesting as diminished hydration, loss of elasticity, and increased wrinkle depth. While oral hydrolyzed collagen peptides (HCPs) are increasingly utilized as systemic nutricosmetics, previous evidence syntheses have been limited by severe methodological heterogeneity and the inability to account for highly influential statistical outliers. This updated systematic review and meta‐analysis evaluated the clinical efficacy of oral collagen peptides for skin rejuvenation using an advanced statistical framework. Methods: A comprehensive literature search was conducted on PubMed (MEDLINE), Cochrane Library, and Google Scholar from inception to November 2025. Randomized controlled trials evaluating oral collagen supplementation in healthy adults were included. Data were synthesized using random effect models. To differentiate true clinical signals from statistical artifacts, analyses were reinforced with multilevel meta‐analysis, leave‐one‐out sensitivity testing, and dose–response spline regressions. Results: Thirty‐five randomized controlled trials comprising 2534 participants were included. Primary analysis revealed that oral collagen supplementation yielded statistically significant improvements in instrumental measures of skin hydration (SMD = 0.44; 95% CI: 0.15–0.73), skin elasticity (SMD = 0.62; 95% CI: 0.15–1.10), and barrier function via reduced transepidermal water loss (SMD = −0.39; 95% CI: −0.62 to −0.16). Efficacy appeared predominantly time‐dependent rather than dose‐dependent, with elasticity and barrier improvements requiring at least 12 weeks of supplementation. Conversely, rigorous sensitivity and multilevel analyses demonstrated that apparent improvements in structural parameters, specifically skin wrinkles, roughness, and dermal density, were statistical artifacts driven by high‐leverage outliers and severe inter‐study heterogeneity. Conclusion: Oral collagen peptide supplementation is an effective functional systemic moisturizer that produces significant time‐dependent improvements in cutaneous hydration, elasticity, and barrier retention. However, current evidence from trials of standard duration remains limited and inconsistent regarding structural anti‐aging effects, including macroscopic wrinkle reduction and dermal densification, and the existing data are simply not robust enough to support definitive conclusions in these domains.

29 March 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HAHassan Ahmad
Hassan Ahmad
FHFathimathul Henna
Fathimathul Henna
SKSANA KHURRAM
SANA KHURRAM
AKAyesha Khan
Ayesha Khan
AAAlisha Ahmed
Alisha Ahmed
AAashfaq Ahmad
ashfaq Ahmad
Acute promyelocytic leukemia (APL) is an aggressive malignancy. Although recent advancements in therapy have improved outcomes, differing toxicity profiles

25 August 2025 in Nursing & Health Sciences
Verified
Journal Article
Closed access
JIJaved Iqbal
Javed Iqbal
BSBrijesh Sathian
Brijesh Sathian
AAashfaq Ahmad
ashfaq Ahmad
ESErica Victoria Stelmaszewski
Erica Victoria Stelmaszewski